Table 3.
Diagnostic value of autoantibody against LRDD, STC1, FOXA1, and EDNRB in human sera by ELISA in the research and validation group.
| TAAb | Se (%) | Sp (%) | YI | LR+ | LR- | PPV (%) | NPV (%) | Accuracy (%) | P |
|---|---|---|---|---|---|---|---|---|---|
| Research group | |||||||||
| LRDD | 79.79 | 90.43 | 0.70 | 8.33 | 0.22 | 89.29 | 81.73 | 85.11 | <0.001 |
| STC1 | 65.96 | 91.49 | 0.57 | 7.75 | 0.37 | 88.57 | 72.88 | 78.72 | <0.001 |
| FOXA1 | 44.68 | 90.43 | 0.35 | 4.67 | 0.61 | 82.35 | 62.04 | 67.55 | <0.001 |
| EDNRB | 12.77 | 91.49 | 0.04 | 1.5 | 0.95 | 60.00 | 51.19 | 52.13 | 0.778 |
| Validation group | |||||||||
| LRDD | 49.26 | 90.44 | 0.40 | 5.15 | 0.56 | 83.75 | 64.06 | 69.85 | <0.001 |
| STC1 | 42.65 | 91.91 | 0.35 | 5.27 | 0.62 | 84.06 | 61.58 | 67.28 | <0.001 |
| FOXA1 | 48.53 | 91.18 | 0.40 | 5.50 | 0.56 | 84.62 | 63.92 | 69.85 | <0.001 |
Abbreviations: OC: ovarian cancer; NHC: normal healthy controls; Se: sensitivity; Sp: specificity; YI: Youden index; LR+: positive likelihood ratio; LR−: negative likelihood ratio; PPV: positive predictive value; NPV: negative predictive value.